Comparative Pharmacology
Head-to-head clinical analysis: NAFAZAIR versus STATROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFAZAIR versus STATROL.
NAFAZAIR vs STATROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
2.5 mg subcutaneously once daily.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours.
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Category C
Category C
Intranasal Antihistamine/Corticosteroid
Otic Antibiotic/Corticosteroid